linolenic acid

Small moleculeexperimental

Alpha-linolenic acid (ALA), an 18-carbon omega-3 essential fatty acid, is the precursor of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA cannot be synthesized by humans and therefore must be entirely acquired from exogenous sources. Evidence for the essentiality of ALA was first provided by a study showing that ALA supplementation reversed the abnormal neurologic signs observed in a 6-year-old girl who suffered from sensory loss and visual complications. Most of the ALA is catabolized via beta-oxidation for energy generation, and a small proportion of it undergoes conversion to produce another two potent members of omega-3 PUFA family: EPA and DHA. Delta 6 desaturase (D6D) enzyme is responsible the conversion of ALA to DHA. Although not conclusive, it was suggested, that the benefits associated with ALA seem to stem mainly from EPA and DHA, and as major consequence of ALA deficiency it appears that EPA and DHA are not adequately produced. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Oct 8, 2021 (NCT05053347)

Timeline

No events for the selected filters.

Indications

Chemistry & pharmacology

Loading structure…

SMILES

CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
Mol. weight
278.4296 g/mol

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05053347N/AOct 8, 2021Huazhong University of Science and Technology
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Huazhong University of Science and TechnologyAcademic/Hospital1112021
1 organizations
Page 1 / 1